Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, discusses the limited treatment options for non-small cell lung cancer (NSCLC) patients without known driver mutations. Dr. Sabari recommends pembrolizumab for patients with high PD-L1, while a combination of pembrolizumab and platinum-doublet chemotherapy is recommended for patients with low PD-L1. He also emphasizes the need for additional predictive biomarkers to identify subsets of patients who may benefit from alternative immune therapies.

Read more by clicking here.